AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10839588
Drug: Protease Inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease Inhibitor (PI)
Trial: 12390317
Drug: Non-Nucleoside Reverse
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Trial: 8749873
Drug: Diltiazem (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (10 mg) intravenous administration
Trial: 28973363
Drug: Lung recruitment
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung recruitment maneuver and PEEP titration according to best respiratory-system compliance (n=501)
Trial: 28973363
Drug: Lung recruitment
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung recruitment maneuver and PEEP titration (n=501)
Trial: 14978636
Drug: Dietary changes,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary changes, use of laxatives, cognitive and behavioral interventions (toilet training)
Trial: 14978636
Drug: Antidiarrheal agents
RxNorm normalized name: ANTIDIARRHEAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiarrheal agents
Trial: 9387948
Drug: Nasal eupnoeic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal eupnoeic inhalation of cold dry air (‐5 degrees C)
Trial: 30559807
Drug: Diet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet therapy for three months
Trial: 30559807
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no diet therapy)
Trial: 23592701
Drug: Early thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early thoracic radiotherapy (TRT) administered concurrently with the first cycle of chemotherapy
Trial: 23592701
Drug: Late thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late thoracic radiotherapy (TRT) administered concurrently with the third cycle of chemotherapy
Trial: 12559643
Drug: Five courses
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five courses of therapy
Trial: 12559643
Drug: Four courses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four courses of therapy
Trial: 12559643
Drug: Five courses
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five courses of therapy (early results)
Trial: 12559643
Drug: Four courses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four courses of therapy (early results)
Trial: 7847530
Drug: Norplant contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norplant contraceptive implants (immediate insertion within 48 hours of delivery)
Trial: 1942508
Drug: Midazolam 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.05 mg.kg‐1 + 10 ml saline
Trial: 1942508
Drug: Midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.1 mg.kg‐1 + 10 ml saline
Trial: 1942508
Drug: Saline only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline only (10 ml)
Trial: 31157368
Drug: National priority
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: National priority for HIV testing and treatment
Trial: 15015438
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Bushen Jianpi Recipe (BJR) and low dosage erythropoietin (EPO) - 50 IU/kg subcutaneous injection twice a week and oral intake of BJR, one dose per day for 3 months.
Trial: 15015438
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) alone - 50 IU/kg subcutaneous injection three times a week for 3 months.
Trial: 9395702
Drug: Acupuncturists/Traditional Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncturists/Traditional Chinese Medicine
Trial: 7933527
Drug: Biapenem (L-627)
RxNorm normalized name: L
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biapenem (L-627) 6 mg/kg
Trial: 7933527
Drug: Biapenem (L-627)
RxNorm normalized name: L
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biapenem (L-627) 12 mg/kg
Trial: 7933527
Drug: Biapenem (L-627)
RxNorm normalized name: L
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biapenem (L-627)
Trial: 3125800
Drug: Intravenous feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous feeding (IVF) alone
Trial: 3125800
Drug: 1 hour
RxNorm normalized name: Product containing precisely estradiol 312.5 nanogram/1 hour prolonged-release vaginal ring (clinical drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 hour of submaximal (51% of VO2max) stationary bicycle exercise daily during IVF
Trial: 31823130
Drug: Dotinurad (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dotinurad (1 mg) administered orally
Trial: 28930490
Drug: Tezacaftor (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezacaftor (100 mg every day) and ivacaftor (150 mg every 12 h)
Trial: 28625368
Drug: Aspirin 100mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100mg/day
Trial: 18214943
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (30 mg elemental Zn daily for 1 year)
Trial: 17030773
Drug: Lamotrigine in
RxNorm normalized name: Product containing lamotrigine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine in combination with valproate
Trial: 17030773
Drug: Users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Users of oral contraceptives comedicated with valproate
Trial: 14646388
Drug: ebastine 20
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ebastine 20 mg
Trial: 17345837
Drug: fexofenadine 120
RxNorm normalized name: fexofenadine hydrochloride 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fexofenadine 120 mg
Trial: 10966901
Drug: Standard TPN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard TPN solution (glutamine-free)
Trial: 9007124
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2 as a 3-hour infusion followed by carboplatin at a dose based on a target area under the concentration-time curve of 6 mg x min/mL.
Trial: 9007124
Drug: Immediate surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate surgery after two courses of neoadjuvant chemotherapy for responding patients.
Trial: 9007124
Drug: Two courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two courses of neoadjuvant chemotherapy for nonresponders before surgery.
Trial: 29061183
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) group (FG) supplemented with 2 g/day of FO concentrate containing 1.8 g of n-3 fatty acids for 30 days
Trial: 29061183
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (PG) received 2 g/day of mineral oil
Trial: 21263414
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of proton pump inhibitors (PPIs)
Trial: 21263414
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (40 mg bolus twice a day for 3 days) of proton pump inhibitors (PPIs)
Trial: 21263414
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of PPIs
Trial: 17366253
Drug: Prize-based incentives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prize-based incentives plus treatment as usual (TAU)
Trial: 15545559
Drug: Standard topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard topical hemostatic agents
Trial: 11273851
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin B-6 (1.6 mg/d) for 12 weeks
Trial: 9500719
Drug: IFN-alpha2a 3
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha2a 3 million units three times per week + Tenoxicam (20 mg/day) during 6 months
Trial: 7850042
Drug: Home program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home program (n = 12) - Cooksey-Cawthorne eye-head exercises performed at home daily for 12 weeks
Trial: 3416548
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A cream (1,000 IU/g)
Trial: 3416548
Drug: Control cream
RxNorm normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cream (without vitamin A)
Trial: 31369180
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of normal saline dressing and 2% mupirocin ointment
Trial: 22082702
Drug: Knowledge and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge and Behavior (K&B) therapy
Trial: 8377718
Drug: Diuretic (hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic (hydrochlorothiazide and triamterene)
Trial: 2854738
Drug: ACTH or
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH or Prednisone therapy
Trial: 24328847
Drug: A compound
RxNorm normalized name: Soma Compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A compound gel containing four amino acids and sodium hyaluronate (Aminogam(®), Errekappa, Italy)
Trial: 24328847
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment involving a drug or gel (Control Group)
Trial: 19661804
Drug: Eritoran tetrasodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eritoran tetrasodium 105 mg
Trial: 19661804
Drug: Eritoran tetrasodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eritoran tetrasodium 45 mg
Trial: 19661804
Drug: Eritoran tetrasodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eritoran tetrasodium 105 mg (high risk subgroup)
Trial: 19661804
Drug: Eritoran tetrasodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eritoran tetrasodium 105 mg (low risk subgroup)
Trial: 18382689
Drug: Mild anemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild anemia (hemoglobin concentration between 10.0 and 11.9 g/dL in women and 10.0 and 12.9 g/dL in men)
Trial: 12771858
Drug: Short-term therapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term therapy with alprostadil (PGE(1))
Trial: 6663640
Drug: Long-term therapy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term therapy
Trial: 10608215
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg cisapride p.o.
Trial: 1962892
Drug: Penbutolol 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol 40 mg/day orally
Trial: 7439241
Drug: Metoprolol 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 300 mg
Trial: 7439241
Drug: Metoprolol 200
RxNorm normalized name: metoprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 200 mg slow-release
Trial: 31185312
Drug: Paravertebral block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral block (PVB) with 10 ml ropivacaine 0.5% at each level from T12 to L1
Trial: 31185312
Drug: Subarachnoid block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid block (SAB) with 15 mg ropivacaine 0.5% at L3–L4 level
Trial: 28220309
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (applied to Groups M and S)
Trial: 12118903
Drug: Darusentan 100
RxNorm normalized name: Darusentan
DrugBank: Darusentan (DB04883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darusentan 100 mg
Trial: 19748665
Drug: Darusentan 300
RxNorm normalized name: Darusentan
DrugBank: Darusentan (DB04883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darusentan 300 mg
Trial: 20509875
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (1 g daily)
Trial: 15302013
Drug: Low-dose rosuvastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rosuvastatin (10 mg daily)
Trial: 31513165
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment (oral intake of Jermuk mineral water, acupuncture, iodine‐bromine baths, massage, exercise therapy, therapeutic enemas)
Trial: 19463204
Drug: Combination inhaled
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination inhaled corticosteroid and long‐acting beta(2)‐agonist (ICS/LABA) maintenance medication
Trial: 17245343
Drug: TEGAFIRI (UFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEGAFIRI (UFT 250 mg m(‐2) day days 1‐14, LV 90 mg day days 1‐14, irinotecan 240 mg m(‐2) day 1; q21)
Trial: 17245343
Drug: TEGAFOX (UFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEGAFOX (UFT 250 mg m(‐2) day days 1‐14, LV 90 mg day days 1‐14, oxaliplatin 120 mg m(‐2) day 1; q21)
Trial: 15738536
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg via 15-minute infusions every 4 weeks for 1 year)
Trial: 12118902
Drug: Limited anti-IL-2R
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Limited anti-IL-2R monoclonal antibody (daclizumab) 2 mg/kg intraoperatively
Trial: 27296660
Drug: Evaluation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of Treatment (EOT) measure
Trial: 27296660
Drug: Treatment satisfaction
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment satisfaction factor
Trial: 22556050
Drug: Neuromuscular warm‐up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular warm‐up programme (15 minutes, targeting core stability, balance, and proper knee alignment, twice a week for one season)
Trial: 19837764
Drug: (90)Y-ibritumomab tiuxetan,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (90)Y-ibritumomab tiuxetan, 14.8 MBq/kg, as consolidation therapy after unlabeled rituximab 250 mg/m(2) on day -7
Trial: 19837764
Drug: (90)Y-ibritumomab tiuxetan,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (90)Y-ibritumomab tiuxetan, 14.8 MBq/kg, as consolidation therapy
Trial: 11733394
Drug: rhuMAb CD18
RxNorm normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: rhuMAb CD18 (0.5 or 2.0 mg/kg)
Trial: 2886716
Drug: Hydrazine sulphate
RxNorm normalized name: benzoic acid 2-(2,4,6-trichlorophenyl)hydrazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrazine sulphate (60 mg three times daily for 30 days)
Trial: 19260845
Drug: Maca dry
RxNorm normalized name: MACA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maca dry extract, 2400 mg
Trial: 12893197
Drug: poly(L-lactide/glycolide) (PLG)
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: poly(L-lactide/glycolide) (PLG) suture
Trial: 27609188
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 8 ml/kg
Trial: 8947448
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume of 14 ml/kg
Trial: 1721597
Drug: Antibiotics combined
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics combined with immunomodulators
Trial: 1721597
Drug: Antibiotics with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics with gamma-globulin
Trial: 31512717
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg Q2W or 150 mg Q2W (depending on baseline LDL-C levels)
Trial: 25234040
Drug: Endometrial infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial infusion of 500 IU of hCG diluted in ET media
Trial: 25234040
Drug: Sham infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham infusion of ET media (Control)
Trial: 23104230
Drug: Daily vitamin
RxNorm normalized name: Daily Vitamin Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vitamin D supplementation (1000 IU)
Trial: 20951986
Drug: Corticosteroid (CS)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (CS) injection after endoscopic balloon dilation (EBD)
Trial: 2450259
Drug: Intravenous nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nicardipine (5 mg/h during 85 min)
Trial: 24165436
Drug: Therapist-aided exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-aided exposure treatment (n = 34)
Trial: 20138810
Drug: Concurrent radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent radiotherapy and letrozole (n=75)
Trial: 20138810
Drug: Sequential radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radiotherapy and letrozole (n=75)
Trial: 15834327
Drug: Preoperative epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative epidural anesthesia with morphine (Group E)
Trial: 15834327
Drug: Inhalation general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation general anesthesia with sevoflurane and intermittent intravenous administration of fentanyl (Group F)
Trial: 10561813
Drug: Nifedipine OROS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine OROS 30 mg once daily (titrated to 60 mg if DBP > 90 mmHg)
Trial: 10561813
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 5 mg once daily (titrated to 10 mg if DBP > 90 mmHg)
Trial: 8722432
Drug: Fosinopril/Hydrochlorothiazide 10/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril/Hydrochlorothiazide 10/12.5 mg
Trial: 8722432
Drug: Fosinopril/Hydrochlorothiazide 20/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril/Hydrochlorothiazide 20/12.5 mg
Trial: 6891699
Drug: Estradiol-17 beta
RxNorm normalized name: ESTRADIOL 17-BETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol-17 beta (200 micrograms, administered every other day for 10 days)
Trial: 6891699
Drug: Testosterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (200 mg, administered every other day for 10 days)
Trial: 6891699
Drug: Dihydrotestosterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydrotestosterone (200 mg, administered every other day for 10 days)
Trial: 25132778
Drug: Ordinary daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary daily activities (control group)
Trial: 22564148
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg weekly dosing after inadequate response to 40 mg eow dosing
Trial: 22564148
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg eow dosing
Trial: 28066879
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg weekly dosing
Trial: 17198705
Drug: Conventional GnRH‐agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional GnRH‐agonist and recombinant FSH stimulation (IVO)
Trial: 15987391
Drug: Remifentanil-based sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil-based sedation regime (initial dose 6 to 9 microg kg(‐1) h(‐1) titrated to response before the addition of midazolam)
Trial: 15987391
Drug: Midazolam-based sedation
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam-based sedation regime with fentanyl or morphine
Trial: 12500172
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with appropriate hormone levels